West Pharma (WST) Tops Q1 EPS by 18c; Bumps Guidance Higher

West Pharma (NYSE: WST) reported Q1 EPS of $2.30, $0.18 better than the analyst estimate of $2.12. Revenue for the quarter came in at $720 million versus the consensus estimate of $720.92 million.

GUIDANCE:

West Pharma sees FY2022 EPS of $9.30-$9.45, versus the prior range of $9.20-$9.35 and the consensus of $9.28.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Is the S&P 500 in an "earnings bubble"? Goldman weighs in
• Amneal gets FDA approval for lanreotide injection, launches immediately